Trials / Completed
CompletedNCT03303599
Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6
Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,118 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The interferon- and ribavirin- (RBV) free combination regimen of glecaprevir plus pibrentasvir (GLE/PIB) for the treatment of genotypes 1 to 6 of chronic hepatitis C (CHC) viral infection has been shown to be safe and effective in randomized controlled clinical trials. This observational study is an effectiveness research examining the regimen of GLE/PIB, used according to local label, under real world conditions in a clinical practice patient population.
Conditions
Timeline
- Start date
- 2017-11-13
- Primary completion
- 2020-01-24
- Completion
- 2020-01-24
- First posted
- 2017-10-06
- Last updated
- 2021-05-19
Locations
156 sites across 9 countries: Austria, Belgium, France, Greece, Israel, Italy, Poland, Portugal, Switzerland
Source: ClinicalTrials.gov record NCT03303599. Inclusion in this directory is not an endorsement.